IPO News Archive

Life sciences company BGMedicine changes terms of IPO

12/6/07


BGMedicine, a life sciences company focused on the development and commercialization of molecular diagnostics based on biomarkers, will now offer their 4.5 million shares at a range of $8.00 to $10.00 as opposed to the previously planned range of $14 to $16. Cowen and Company is the sole book runner on the deal.

View IPO Profile: BGMD         
Source: www.RenaissanceCapital.com
Latest User Comments
Attribution Policy: The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital, Greenwich, CT (www.renaissancecapital.com).
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital and/or the IPO Plus Fund (symbol: IPOSX) may have investments in securities of companies mentioned.
Invest in the IPO Plus Fund
About Fund Prospectus Invest